ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,786.02
-0.17%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) Noticias

PBLA Panbela Therapeutics Inc

1.11
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Panbela Therapeutics Inc PBLA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 1.11 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.11 1.11
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/5/202415:15GLOBEPanbela to Host First Quarter 2024 Earnings Conference Call..
30/4/202407:00GLOBEAcceptance of Eflornithine (DFMO) Abstract for Oral..
26/4/202415:39EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
25/4/202415:36EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
25/4/202415:35EDGAR2Form 8-K - Current report
25/4/202408:09EDGAR2Form 25-NSE - Notification filed by national security..
22/4/202407:02EDGAR2Form 8-K - Current report
22/4/202407:00GLOBEPanbela Therapeutics Announces Interim Data Analysis for..
18/4/202415:31EDGAR2Form S-1 - General form for registration of securities under..
18/4/202407:00GLOBEPanbela Announces Poster Presentation at American..
17/4/202407:36EDGAR2Form 8-K - Current report
16/4/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
16/4/202416:29GLOBEPanbela Announces Transfer to OTCQB Market
04/4/202415:17EDGAR2Form DEF 14A - Other definitive proxy statements
29/3/202416:24EDGAR2Form S-1 - General form for registration of securities under..
29/3/202416:08EDGAR2Form POS AM - Post-Effective amendments for registration..
26/3/202415:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
26/3/202415:12EDGAR2Form 8-K - Current report
26/3/202415:10GLOBEPanbela Provides Business Update and Reports Q4 and FY 2024..
26/3/202406:21IHMARKETNEWSU.S. Index Futures on the Rise, Oil Prices Show Stability
25/3/202415:15EDGAR2Form PRE 14A - Other preliminary proxy statements
12/3/202415:15GLOBEPanbela to Host Fourth Quarter and Year End 2023 Earnings..
07/3/202405:01EDGAR2Form 8-K - Current report
15/2/202407:05EDGAR2Form 8-K - Current report
15/2/202407:00GLOBEPanbela Regains Compliance with Nasdaq Listing Standards for..
13/2/202419:10EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202416:24EDGAR2Form 8-K - Current report
01/2/202406:15EDGAR2Form 8-K - Current report
01/2/202406:00GLOBEPanbela Announces Closing of Approximately $9.0 Million..
30/1/202416:28EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
30/1/202407:15GLOBEAcceptance of Ivospemin (SBP-101) Abstract for Poster..
29/1/202405:21EDGAR2Form 8-K - Current report
29/1/202405:15GLOBEPanbela Announces Pricing of Approximately $9.0 Million..
25/1/202411:22EDGAR2Form S-1/A - General form for registration of securities..
25/1/202407:54EDGAR2Form S-1/A - General form for registration of securities..
25/1/202406:00GLOBEPanbela Exceeds 50% Enrollment for Aspire Trial in..
22/1/202405:08EDGAR2Form S-1/A - General form for registration of securities..
19/1/202416:20EDGAR2Form 8-K - Current report
18/1/202407:15GLOBEPanbela Announces Publication of Clinical Data Titled: Phase..
16/1/202407:00GLOBEPanbela Announces 1-for-20 Reverse Stock Split Effective..
05/1/202415:34EDGAR2Form S-8 - Securities to be offered to employees in employee..
21/12/202308:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/12/202308:25EDGAR2Form 8-K - Current report
21/12/202308:15GLOBEPanbela Therapeutics Announces Exercise of Warrants and..
21/12/202305:00EDGAR2Form 8-K - Current report
18/12/202307:15GLOBEPanbela Therapeutics Announces US WorldMeds NDA Approval for..
04/12/202307:00GLOBEPanbela Announces Publication of Abstract Titled: Evaluation..
01/12/202315:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/12/202315:15EDGAR2Form 8-K - Current report
29/11/202307:15GLOBEPanbela Announces 2nd Independent Safety Review of the..

Su Consulta Reciente

NASDAQ
PBLA
Panbela Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados